Campbell & CO Investment Adviser LLC
Position in ROIV — Roivant Sciences Ltd.
CIK 1353570
BALTIMORE, MD
Position in ROIV
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$435,403
-$105,539 QoQ
Shares Held
12,303
-65.6% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#297
of 494 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names. ROIV ranks #35 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ROIV
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $435,403 | 12,303 | Shares | Sole | 2026-08-03 | |
| 2025-09-30 | $540,942 | 35,753 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $1,177,241 | 104,458 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $244,702 | 24,252 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $922,870 | 78,011 | Shares | Sole | 2025-02-10 | |
| No filing history on record for this holder in this stock. | ||||||